Antibody-drug conjugates such as Polatuzumab Vedotin, a humanized CD79b antibody conjugate with a potent mitosis inhibitor monomethyl auristatin (Plivy®, Roche), and Inotuzumab Ozogamicin, a humanized CD22 antibody linked to the cytotoxic antibiotic calicheamicin (Besponsa®, Pfizer/Wyeth), combine the capabilities of tumor cell targeting and tumor cell elimination [25,26]. The gene discussed is CD22; the disease is neoplasm.